MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, ALDX had $18,099,330 increase in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
$18,099,330

Unit: Dollar
Cash Flow
2025-09-30
2025-06-30
Net loss
-7,688,341 -19,696,813
Stock-based compensation
2,580,754 2,420,578
Non-cash interest expense
50,368 117,525
Net amortization of premium on marketable securities
266,560 838,915
Depreciation and amortization expense
63,683 123,194
Write-off of deferred offering costs
0 267,261
Prepaid expenses and other current assets
-50,152 -708,358
Accounts payable
-1,016,107 849,077
Accrued expenses and other liabilities
-795,365 -4,975,186
Net cash used in operating activities
-7,021,416 -21,024,921
Purchases of marketable securities
0 40,263,712
Maturities of marketable securities
25,000,000 47,000,000
Net cash provided by (used in) investing activities
25,000,000 6,736,288
Proceeds from issuance of common stock, net of issuance costs
0 -
Proceeds from exercise of stock options
120,746 983,194
Proceeds from employee stock purchase plan
0 19,616
Net cash provided by financing activities
120,746 1,002,810
Net increase (decrease) in cash and cash equivalents
18,099,330 -13,285,823
Cash and cash equivalents at beginning of period
54,527,092 -
Cash and cash equivalents at end of period
59,340,599 -
Unit: Dollar

Time Plot

Show the time plot by selecting a row from the table.

Aldeyra Therapeutics, Inc. (ALDX)

Aldeyra Therapeutics, Inc. (ALDX)